Abstract 5093
Background
PDR (Pulsed Dose Rate) Brachytherapy is one of the treatments of choice for cervical cancer. Main side-effects are vaginal dryness, dyspareunia, pain, stenosis and sexual dysfunction that impacts on the patient’s well-being and on quality of life. To evaluate the efficacy of vaginal moisture to reduce dryness and pain associated with PDR Brachytherapy in cervical cancer patients treated at Catalan Institute of Oncology-Barcelona.
Methods
A quasi-experimental randomized study. From 2016 to 2018 all women were assessed by nurses 4 times: basal at discharge, 1st, 3rd and 6th month post-treatment. Experimental intervention with moisturizing versus standard care. Inclusion criteria; women diagnosed of cervical cancer receiving PDR. Probabilistic sampling of patients assigned 42 to control group CG and 47 to experimental group (EG). Variables: vaginal hydration, pain, age, ethnicity, comfort perceived, socio-demographic, tobacco, sexual relationship and couples. Instruments: LENT/SOMA to assess vaginal toxicity and visual numeric for pain.
Results
Of the 96 eligible, some excluded for relapse, or study failure. N = 89 women. Mean age: 52.78 + 12.8 (range 24-83) years old. Ethnicity; 63.8% white, Latina 3.1%, Arabic and Asiatic 0.8% each and gypsies 1.6%. Education; 3.1% illiteracy, primary 32.2%, secondary 25.2% and university 7.2%. Smokers 29.2%. For variable pain was 15-15-17-15 in CG and 20-17-15-13 in EG for consecutive points. Dyspareunia was present in 0-4-8-7 patients and 3-0-2-2 in EG. Dryness was 1-9-13-12 in CG and 6-1-8-10 in EG. Bleeding was 17-5-5-7 in CG and 16-10-0-6 in EG. Only significance differences on dryness variable. A total of 48.31% women avoid sexual intercourse, 22 (24.71%) in CG and 21 (23.59%). No significance differences.
Conclusions
An early vaginal moisturizing post-brachytherapy decreases the appearance of dyspareunia, allows start sexual relationships and improves the quality of life and sense of well-being. However some patients do not give the necessary importance to sexuality and it is something that they put aside during the treatment. Nursing education for patients at discharge helps to facilitate a healthy sexuality.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5705 - External validation and longitudinal extension of the LIPI (Lung Immune Prognostic Index) for immunotherapy outcomes in advanced non-small cell lung cancer.
Presenter: Jakob Riedl
Session: Poster Display session 3
Resources:
Abstract
5758 - Changes of TCR Repertoire in Metastatic Renal Cell Carcinoma and Metastatic Melanoma Patients Treated with Nivolumab
Presenter: Martin Klabusay
Session: Poster Display session 3
Resources:
Abstract
1743 - Expression of MHC class I, HLA-A and HLA-B identifies immune activated breast tumors with favorable outcome
Presenter: María Del Mar Noblejas López
Session: Poster Display session 3
Resources:
Abstract
2219 - Prognostic Significance of Tumor Tissue NeuGcGM3 Ganglioside Expression and Predictive Value of Circulating Tumor Cell Count Monitoring in Patients Receiving Racotumomab Immunotherapy
Presenter: Necdet Üskent
Session: Poster Display session 3
Resources:
Abstract
2996 - Evolution of Myeloid-Derived Suppressor Cells and Objective Response Rate in Relapsed/Refractory Diffuse Large B Cell Lymphoma (R/R DLBCL) patients after receiving immunotherapy
Presenter: Carlos Jiménez Cortegana
Session: Poster Display session 3
Resources:
Abstract
2110 - A Phase Ia/Ib trial of the anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas
Presenter: Lin Shen
Session: Poster Display session 3
Resources:
Abstract
3515 - Results from a randomised Phase 1/2 trial evaluating the safety and antitumour activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma (ccRCC)
Presenter: Martin Voss
Session: Poster Display session 3
Resources:
Abstract
3566 - Pembrolizumab in Advanced Rare Cancers
Presenter: Aung Naing
Session: Poster Display session 3
Resources:
Abstract
3567 - High clinical benefit rates of pembrolizumab in very rare sarcoma histotypes: first results of the AcSé Pembrolizumab study
Presenter: Jean-Yves Blay
Session: Poster Display session 3
Resources:
Abstract
2421 - Lenvatinib plus PD-1 blockade in advanced bile tract carcinoma.
Presenter: Jianzhen Lin
Session: Poster Display session 3
Resources:
Abstract